Zenas BioPharma Receivables 2023-2025 | ZBIO

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Zenas BioPharma receivables from 2023 to 2025. Receivables can be defined as the total amount of collectibles for a company

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Zenas BioPharma receivables from 2023 to 2025. Receivables can be defined as the total amount of collectibles for a company

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$214.8B
Amgen (AMGN)	$160.4B
Gilead Sciences (GILD)	$135.3B
Vertex Pharmaceuticals (VRTX)	$119B
Bristol Myers Squibb (BMY)	$97.8B
CSL (CSLLY)	$78.3B
GSK (GSK)	$74.7B
Regeneron Pharmaceuticals (REGN)	$59.4B
Alnylam Pharmaceuticals (ALNY)	$42.3B
Argenex SE (ARGX)	$35B
BioNTech SE (BNTX)	$26.7B
Royalty Pharma (RPRX)	$19.9B
Insmed (INSM)	$19.8B
Biogen (BIIB)	$18.9B
Illumina (ILMN)	$15.5B
Genmab (GNMSF)	$14.5B
Genmab (GMAB)	$14.1B
Incyte (INCY)	$13.3B
Moderna (MRNA)	$12.5B
Exelixis (EXEL)	$12.2B
BioMarin Pharmaceutical (BMRN)	$11.2B
Ascendis Pharma (ASND)	$10.8B
QIAGEN (QGEN)	$10.7B
Swedish Orphan Biovitrum (BIOVF)	$10.6B
Exact Sciences (EXAS)	$9.8B
Verona Pharma American Depositary Share (VRNA)	$8.9B
Bio-Techne Corp (TECH)	$8.4B
Blueprint Medicines (BPMC)	$8.3B
Roivant Sciences (ROIV)	$7.9B
Legend Biotech (LEGN)	$7.7B